Posted on 12/22/21
| News Source: Arutz-7
Assuta Hospital in Ashdod has published a new groundbreaking research showing that the booster dose of the COVID-19 vaccine increases by 40 times the number of antibodies found in immunocompromised patients.
Recent research from around the world has shown a drop in the number of antibodies starting a few months after the second dose, alongside an extreme and encouraging rise following the administration of a booster dose in the general population.
The Assuta research shows that this data holds true for those who are immunocompromised as well.
Prof. Adi Leiba, an internal medicine, nephrology, and blood pressure expert in Israel and in MA, USA, who also serves as Deputy Director General of Assuta Ashdod and is one of the lead researchers for the groundbreaking study, said, "The data shows that receiving two doses of the vaccine is not enough, while the third dose is essentially a game changer, not just for the general population but also for those who are chronically ill."
Dr. Tal Brosh, Head of Infectious Disease Unit at Assuta Ashdod, said, "This research proves that the administration of a booster dose to patients who are severely chronically ill may provide good protection from illness from Omicron."
The research, led by Prof. Leiba, Dr. Brosh, and Dr. Avital Angel Korman, who runs the hospital's dialysis unit, examined 61 dialysis patients, whose antibody levels were evaluated following the second dose of the vaccine, and later following the third dose.
The results showed clearly and dramatically the necessity of a third vaccine, in light of the low antibody levels just months after the second dose.